Literature DB >> 25083421

Paradoxical roles for FOXA1 in anti-estrogen resistance and as a luminal differentiation factor in breast cancer.

M A Christine Pratt1.   

Abstract

Entities:  

Year:  2012        PMID： 25083421      PMCID： PMC4115716          DOI： 10.3978/j.issn.2227-684X.2012.04.06

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  14 in total

1.  FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Authors:  Sunil Badve; Dmitry Turbin; Mangesh A Thorat; Akira Morimiya; Torsten O Nielsen; Charles M Perou; Sandi Dunn; David G Huntsman; Harikrishna Nakshatri
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

3.  Predicting the clinical status of human breast cancer by using gene expression profiles.

Authors:  M West; C Blanchette; H Dressman; E Huang; S Ishida; R Spang; H Zuzan; J A Olson; J R Marks; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

4.  Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.

Authors:  Torsten A Hopp; Heidi L Weiss; Irma S Parra; Yukun Cui; C Kent Osborne; Suzanne A W Fuqua
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

5.  FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Authors:  Rutika J Mehta; Rohit K Jain; Samuel Leung; Jennifer Choo; Torsten Nielsen; David Huntsman; Harikrishna Nakshatri; Sunil Badve
Journal:  Breast Cancer Res Treat       Date:  2011-04-19       Impact factor: 4.872

6.  A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.

Authors:  Georgios P Skliris; Zoann J Nugent; Brian G Rowan; Carla R Penner; Peter H Watson; Leigh C Murphy
Journal:  Endocr Relat Cancer       Date:  2010-06-03       Impact factor: 5.678

7.  Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

Authors:  Foluso O Ademuyiwa; Mangesh A Thorat; Rohit K Jain; Harikrishna Nakshatri; Sunil Badve
Journal:  Mod Pathol       Date:  2009-11-27       Impact factor: 7.842

8.  FOXA1 represses the molecular phenotype of basal breast cancer cells.

Authors:  G M Bernardo; G Bebek; C L Ginther; S T Sizemore; K L Lozada; J D Miedler; L A Anderson; A K Godwin; F W Abdul-Karim; D J Slamon; R A Keri
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

9.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Authors:  Caryn S Ross-Innes; Rory Stark; Andrew E Teschendorff; Kelly A Holmes; H Raza Ali; Mark J Dunning; Gordon D Brown; Ondrej Gojis; Ian O Ellis; Andrew R Green; Simak Ali; Suet-Feung Chin; Carlo Palmieri; Carlos Caldas; Jason S Carroll
Journal:  Nature       Date:  2012-01-04       Impact factor: 49.962

10.  Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Authors:  M A Thorat; C Marchio; A Morimiya; K Savage; H Nakshatri; J S Reis-Filho; S Badve
Journal:  J Clin Pathol       Date:  2007-11-23       Impact factor: 3.411
View more
  3 in total

1.  Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.

Authors:  Cheng Wang; Yun-Hao Pan; Ming Shan; Ming Xu; Jia-Lin Bao; Li-Ming Zhao
Journal:  Int J Mol Sci       Date:  2015-03-02       Impact factor: 5.923

2.  FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6.

Authors:  Xiaofeng Dai; Hongye Cheng; Xiao Chen; Ting Li; Jia Zhang; Guoyin Jin; Dongyan Cai; Zhaohui Huang
Journal:  Int J Biol Sci       Date:  2019-04-21       Impact factor: 6.580

3.  Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.

Authors:  Elie Dagher; Violette Royer; Paul Buchet; Jérôme Abadie; Delphine Loussouarn; Mario Campone; Frédérique Nguyen
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.